PRA Advisors™ offers high-end expertise to help life sciences decision-makers address pricing, reimbursement, access and value challenges globally and locally.
HTA Submission Australia
A mid sized radiation oncology firm needed help to reconstruct its cost-utility and cost-effectiveness analyses and re-submit the reimbursement dossier to the Medical Services Advisory Committee (MSAC) in Australia.
bizi assembled a team of two: a seasoned health economic modeler and a local data consultant. The expert team successfully reconstructed the economic models informed by local cost and physician survey data. Our health economist also played an instrumental role in interacting with the Australian HTA agency during the re-submission process.
Reimbursement Feasibility Analysis - Germany
A specialty pharma needed to determine the likelihood, with expected cost/timeline, that their new drug-device combo product will be reimbursed in Germany.
bizi engaged a German HTA expert and conducted a thorough review and analysis of prior HTA and reimbursement practices for the therapeutic area in Germany, including the ‘additional benefit assessment’ by G-BA and IQWiG.
Information and analysis included: how products obtain reimbursement, the pathway to achieving that, and a specific examination of how similar or competing products for the same indication achieved reimbursement and the data required of them. The analysis results were further validated through local KOL interviews.
Reimbursement Planning - China
A global oncology firm needed help to understand oncology drug reimbursement practices in China at both national and regional levels to help inform reimbursement planning and a preliminary value framework.
bizi engaged a local China expert who had first-hand success negotiating National Reimbursement Drug Listing with NHSA to conduct the review.
Information and analysis included: an in-depth understanding of China’s innovative drug reimbursement practices at both national and regional levels; disease epidemiology and Standard of Care in China; clinical and economic evidence required for the indication to support pricing negotiations and past reimbursement practices for the indication at national and regional levels.
Speaker Series for a Multi-National APAC Division
A multi-national pharmaceutical APAC division market access team was looking for expert speakers to help enhance the local team’s understanding and capability on several key topics from HTA, comparative-effectiveness research, P & T committee decision-making process, budget impact analysis to the roll-out of DRG system in China.
bizi assembled a team of subject matter experts to address individual topics and successfully delivered five training sessions for the company.
Market Access Lead – US and Europe
A specialty startup firm needed in house expertise to head up its market access function as the company entering into phase2b development.
bizi engaged a market access expert with both US and EU expertise.
The consultant successfully supported the client with key tasks, including (1) Leading pricing and payer research in the US and Europe; (2) Integrating payer requirements into an asset development plan; (3) Developing product value propositions; (4) Leading AMCP and global value dossier development; (5) Contributing to customer-facing model development (e.g., Budget Impact Analysis) supporting field communications.
Cardiovascular Product Launch US
An MNC needed reimbursement expertise in inpatient and outpatient settings to support its cardiovascular product launch in the US.
bizi engaged a seasoned reimbursement consultant with strong working relationships with Medicare and major commercial insurers in the US.
The project focused on: (1) Understand Medicare and leading private insurers’ coverage, payment, and coding policies relative to Company’s technology in different care settings. (2) Guide and influence the company's reimbursement strategy. (3) Inform phase 3 trial design. (4) Craft and test product value messaging. (5) Understand payer perception of key value drivers for higher prices. (6) Assess the impact that various pricing levels will have on payer payment. (7) Anticipate likely payer management given the competitive landscape. (8) Lay the foundation of a robust publication plan timed with the Company’s launch timeline.